TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9740484

Group type: EXPERIMENTAL
Intervention: Coronary angiograms (quantitative coronary angiography)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Baseline number of all stenoses
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Non-fatal myocardial infarcts and revascularization procedures
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: High-grade stenoses in the left anterior descending artery
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Baseline left ventricular ejection fraction
Number of subjects: 419
Study: 7873476

Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 3145014

Group type: EXPERIMENTAL
Intervention: 2 g cephradine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 5 g mezlocillin
Number of subjects: 400

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 6 g cephradine
Number of subjects: 400
Study: 29920432

Group type: EXPERIMENTAL
Intervention: Potential child abuse occurring in their neighborhood
Number of subjects: 946

Group type: COMPARATOR
Intervention: Potential child abuse in an unfamiliar neighborhood
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Higher collective efficacy scores
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences
Number of subjects: 946
Study: 26935243

Group type: EXPERIMENTAL
Intervention: Compression use during exercise intervention
Number of subjects: 41
Study: 25363124

Group type: EXPERIMENTAL
Intervention: HAPA-based intervention with family support
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 22613524

Group type: EXPERIMENTAL
Intervention: Dual-axis rotational coronary angiography (DARCA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard coronary angiography (SA)
Number of subjects: 200
Study: 19362286

Group type: EXPERIMENTAL
Intervention: Stapled transanal rectal resection alone or associated with transobturator tape, vaginal repair of the enterocele, or vaginal hysterectomy
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Combination of rectal and urogynecologic surgery with vaginal hysterectomy
Number of subjects: 142
Study: 17720629

Group type: EXPERIMENTAL
Intervention: Bayesian approach incorporating external and subjective information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formal synthesis of external evidence
Number of subjects: 0
Study: 16001909

Group type: EXPERIMENTAL
Intervention: Hamstring stretching
Number of subjects: 1338
Study: 11909508

Group type: EXPERIMENTAL
Intervention: Education plus behavior management group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Education only group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 10322619

Group type: EXPERIMENTAL
Intervention: Personality traits and cognitive styles (hopelessness, neuroticism, introversion, low self-esteem, impulsiveness, external locus of control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (individuals not making suicide attempts)
Number of subjects: 0
Study: 8701892

Group type: EXPERIMENTAL
Intervention: Bolus recombinant urokinase (rUK) administered as three bolus infusions of 1 million U over a 24-hour period
Number of subjects: 17

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bolus recombinant urokinase (rUK)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 17
Study: 8370856

Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Nondirective (ND) therapy
Number of subjects: 3
Study: 2873756

Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 153
Study: 29432644

Group type: EXPERIMENTAL
Intervention: BF-200 ALA (5-aminolaevulinic acid gel)
Number of subjects: 281

Group type: COMPARATOR
Intervention: MAL (methyl aminolaevulinate cream)
Number of subjects: 281
Study: 27769226

Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Baseline diagnosis of psychosis
Number of subjects: 237
Study: 26089301

Group type: EXPERIMENTAL
Intervention: Vitrification
Number of subjects: 307

Group type: COMPARATOR
Intervention: Slow freezing
Number of subjects: 307
Study: 23925143

Group type: EXPERIMENTAL
Intervention: Calfactant surfactant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21569169

Group type: EXPERIMENTAL
Intervention: Educational intervention combining a feedback curriculum with a card system
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (current feedback method)
Number of subjects: 15
Study: 19468050

Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen plus medroxyprogesterone acetate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hormone therapy (general)
Number of subjects: 16
Study: 16306466

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 6602

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 6602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6602
Study: 12826700

Group type: EXPERIMENTAL
Intervention: recombinant follicle-stimulating hormone (recFSH) 2 x 225 IU per week + hCG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: recombinant follicle-stimulating hormone (recFSH) 3 x 150 IU per week + hCG
Number of subjects: 30

Group type: COMPARATOR
Intervention: hCG alone (pre-treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined gonadotropin treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subjects with a history of maldescended testes
Number of subjects: 30
Study: 10709886

Group type: EXPERIMENTAL
Intervention: HIV-infected children
Number of subjects: 18

Group type: COMPARATOR
Intervention: HIV-seroreverter children
Number of subjects: 18
Study: 7793186

Group type: EXPERIMENTAL
Intervention: Plain 0.15% bupivacaine (150 mg.100 ml‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline (1.5 micrograms ml‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 1828183

Group type: EXPERIMENTAL
Intervention: LHRH analogue Zoladex (administered subcutaneously every 28 days)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: LHRH analogue Zoladex
Number of subjects: 358
Study: 6758745

Group type: EXPERIMENTAL
Intervention: Aspirin (1950 mg/day orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg/day orally)
Number of subjects: 0
Study: 30166425

Group type: EXPERIMENTAL
Intervention: Automatically titrated O2 flows (FreeO2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Constant O2 flow
Number of subjects: 12
Study: 28368940

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New formula for estimating blood loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulas of Gross, Bourke and Smith, and Camarasa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Camarasa's formula
Number of subjects: 0
Study: 25765144

Group type: EXPERIMENTAL
Intervention: Open Monitoring (OM)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Focused Attention (FA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: General Relaxation (Control)
Number of subjects: 32
Study: 23848826

Group type: EXPERIMENTAL
Intervention: 10-mg TZP-102 once daily for 12 weeks
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 20-mg TZP-102 once daily for 12 weeks
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 10-mg TZP-102 three-times-daily for 12 weeks (Study TZP-102-CL-G004)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo three-times-daily for 12 weeks (Study TZP-102-CL-G004)
Number of subjects: 201
Study: 22006729

Group type: EXPERIMENTAL
Intervention: 1,470 nm diode laser (4-5 W power)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 940 nm diode laser (12 W power)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1,470 nm diode laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: 940 nm diode laser
Number of subjects: 20
Study: 19833272

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.25%
Number of subjects: 66

Group type: COMPARATOR
Intervention: lidocaine 0.5%
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%
Number of subjects: 66
Study: 16710890

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Group B)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham acupuncture (Group C)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard FBS with airway topic anesthesia (Group A)
Number of subjects: 48
Study: 14722679

Group type: EXPERIMENTAL
Intervention: 4D‐MSPECT
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: QGS
Number of subjects: 54
Study: 11385055

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (three times daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9089426

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (7.8 mg/24 hr)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline (drug-free) response to tyramine
Number of subjects: 15
Study: 7824763

Group type: EXPERIMENTAL
Intervention: Adinazolam 30 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adinazolam 60 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adinazolam 90 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3278631

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31634450

Group type: EXPERIMENTAL
Intervention: Active iTBS
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 14
Study: 28589238

Group type: EXPERIMENTAL
Intervention: Rifaximin (550 mg three times daily for 2 weeks, followed by two 2-week repeat courses)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 26608978

Group type: EXPERIMENTAL
Intervention: Nutrition Support Team (NST)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 23142439

Group type: EXPERIMENTAL
Intervention: 5mg zoledronic acid intravenous infusion
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 21251030

Group type: EXPERIMENTAL
Intervention: Prebiotics, probiotics, and synbiotics
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 9
Study: 18645274

Group type: EXPERIMENTAL
Intervention: Modified-release doxazosin 4 mg, once a day in the morning, for 2 years
Number of subjects: 65

Group type: COMPARATOR
Intervention: Bladder catheterization without medication
Number of subjects: 65
Study: 17142523

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity (measured in estimated-metabolic-equivalent hours)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Intense physical activity (measured in hours)
Number of subjects: 663
Study: 12548324

Group type: EXPERIMENTAL
Intervention: A single course of corticosteroids (two 12 mg doses of betamethasone given IM 24 hours apart, or four 6 mg doses of dexamethasone given IM 12 hours apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat courses of corticosteroids (not routinely recommended)
Number of subjects: 0
Study: 11049894

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) administered in two bolus doses of 10 mg/kg each, plus a continuous infusion of 1.0 mg/kg/h for 10 hours after the first bolus.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) administered as described above.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no tranexamic acid).
Number of subjects: 40
Study: 8694209

Group type: COMPARATOR
Intervention: Standard arrangement of the T piece
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Longer expiratory limb
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Altered T piece arrangement
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Increased length of the inspiratory limb
Number of subjects: 10
Study: 1558239

Group type: EXPERIMENTAL
Intervention: Dyonics Dynamic Cruciate Tester
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acufex Knee Signature System
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: KT‐1000
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stryker Knee Laxity Tester
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Genucom Knee Analysis System
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: KSS
Number of subjects: 100
Study: 3994882

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture of pancuronium and tubocurarine
Number of subjects: 0
Study: 30111216

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.50% ropivacaine (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (Group C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anesthesia only (Group D)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison between Groups B and C
Number of subjects: 120
Study: 26666519

Group type: EXPERIMENTAL
Intervention: 250 mg carnitine supplements
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24671945

Group type: EXPERIMENTAL
Intervention: Tight glycemic control (TGC)
Number of subjects: 980

Group type: COMPARATOR
Intervention: Standard care (STD)
Number of subjects: 980
Study: 22491538

Group type: EXPERIMENTAL
Intervention: Air transport
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Ground transport
Number of subjects: 2049
Study: 20222892

Group type: EXPERIMENTAL
Intervention: MMR vaccine (TRESIVAC(R)) containing Leningrad-Zagreb mumps strain
Number of subjects: 453119

Group type: COMPARATOR
Intervention: Control group (younger children)
Number of subjects: 453119
Study: 17079694

Group type: EXPERIMENTAL
Intervention: Cisplatin plus Irinotecan (IP)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Carboplatin plus Paclitaxel (TC)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Cisplatin plus Gemcitabine (GP)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Cisplatin plus Vinorelbine (NP)
Number of subjects: 602
Study: 16305592

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 10
Study: 12152000

Group type: EXPERIMENTAL
Intervention: Enfuvirtide 45 mg (subcutaneous)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enfuvirtide 90 mg (subcutaneous)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enfuvirtide 180 mg (subcutaneous)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enfuvirtide 90 mg (intravenous)
Number of subjects: 12
Study: 10202343

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP; 800 microg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Inhaled beta2‐agonists alone
Number of subjects: 14
Study: 8525222

Group type: EXPERIMENTAL
Intervention: Computer multimedia program (independent study program on hypertension)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Classical lectures (control group)
Number of subjects: 100
Study: 2203251

Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet (total fat intake reduced from 37% to 21% of calories, carbohydrate intake increased from 44% to 52% of calories)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet
Number of subjects: 0
Study: 11086

Group type: EXPERIMENTAL
Intervention: Cimetidine (4 X 200 mg/d p.o.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 12
Study: 31274363

Group type: EXPERIMENTAL
Intervention: 8-hour resiliency program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 27203734

Group type: EXPERIMENTAL
Intervention: VONCENTO (plasma-derived VWF/FVIII concentrate)
Number of subjects: 21
Study: 25371035

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT; 3‐min intervals at 40% and 80% V̇O2max)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MCT; sustained 60% V̇O2max)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (CTL) group (no training)
Number of subjects: 60
Study: 23473350

Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg/d for 2 weeks
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d for 2 weeks
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg/d for 1 week, increased to 80 mg/d on day 8 for week 2
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Lurasidone (flexibly dosed 40-120 mg/d for subsequent 4 weeks)
Number of subjects: 240
Study: 21703067

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ferric sulfate (FS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Zinc oxide eugenol (ZOE)
Number of subjects: 32
Study: 19027101

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 17420681

Group type: EXPERIMENTAL
Intervention: Intensive cognitive-behavioral therapy (CBT) - 14 sessions of daily psychotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Weekly cognitive-behavioral therapy (CBT) - 14 sessions of weekly psychotherapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intensive cognitive-behavioral therapy (CBT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Weekly cognitive-behavioral therapy (CBT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Children's Yale‐Brown Obsessive‐Compulsive Scale
Number of subjects: 40
Study: 15136305

Group type: EXPERIMENTAL
Intervention: Moderate or severe reductions in GFR (30-59 mL/min per 1.73 m² and <29 mL/min per 1.73 m²)
Number of subjects: 40514

Group type: EXPERIMENTAL
Intervention: Decrease in GFR of 10 mL/min per 1.73 m²
Number of subjects: 40514

Group type: EXPERIMENTAL
Intervention: GFR of approximately 60 to 70 mL/min per 1.73 m²
Number of subjects: 40514
Study: 11277132

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage and customized compression garments
Number of subjects: 11
Study: 9551245

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg once daily for 5 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ofloxacin 600 mg divided into three doses for 5 days
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg once daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ofloxacin 600 mg divided into three doses
Number of subjects: 150
Study: 7936839

Group type: EXPERIMENTAL
Intervention: N-terminal propeptide of type III procollagen (PIIINP) concentration measured by Fab'-fragment and whole antibody-based RIA assay in cord serum and amniotic fluid
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: N-terminal propeptide of type III procollagen (PIIINP) concentration
Number of subjects: 602
Study: 3215203

Group type: EXPERIMENTAL
Intervention: Theo-Dur Sprinkle (TDS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Theophylline elixir
Number of subjects: 8
Study: 29547234

Group type: EXPERIMENTAL
Intervention: KED‐XT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: KED
Number of subjects: 50

Group type: COMPARATOR
Intervention: KED vs KED‐XT
Number of subjects: 50
Study: 27325335

Group type: EXPERIMENTAL
Intervention: Bevacizumab (lower dose 7.5 mg/kg)
Number of subjects: 0
Study: 24735616

Group type: EXPERIMENTAL
Intervention: Long inpatient multicomponent rehabilitation program (3 ½ weeks with full rehabilitation days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short inpatient multicomponent rehabilitation program (4+4 full days, separated by two weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient cognitive behavioral therapy group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care reference group (untouched control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long inpatient multicomponent rehabilitation program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short inpatient multicomponent rehabilitation program
Number of subjects: 0
Study: 24059292

Group type: EXPERIMENTAL
Intervention: AIMS intervention
Number of subjects: 230

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 230
Study: 20841517

Group type: EXPERIMENTAL
Intervention: Continuing Professional Development (CPD) workshops (3 workshops)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional Continuing Pharmacy Education (CPE)
Number of subjects: 100
Study: 18000691

Group type: EXPERIMENTAL
Intervention: Xialine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 16042894

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily for up to 5 years
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Continuation of lamivudine therapy after HBeAg seroconversion
Number of subjects: 81
Study: 12357479

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol at high relative humidity (> 90%)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol at low relative humidity (13%)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol at intermediate relative humidity (room air)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison of droplet size distributions
Number of subjects: 9